Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:2515-2523

This Article
Right arrow Full Text
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andersen, H. O.
Right arrow Articles by Nordestgaard, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andersen, H. O.
Right arrow Articles by Nordestgaard, B. G.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:2515-2523.)
© 1997 American Heart Association, Inc.


Articles

Dose-Dependent Suppression of Transplant Arteriosclerosis in Aorta-Allografted, Cholesterol-Clamped Rabbits

Suppression Not Eliminated by the Cholesterol-Raising Effect of Cyclosporine

Henrik Ørbaek Andersen; Pernille Holm; Steen Stender; Birgit Fischer Hansen; ; Børge Grønne Nordestgaard

From the Departments of Thoracic Surgery (H.O.A.) and Clinical Biochemistry (H.O.A., P.H.), Rigshospitalet, Hellerup; the Clinical Institute, University of Odense (S.S.), Odense; the Department of Pathology, Hvidovre Hospital (B.F.H.), Hvidovre; and the Department of Clinical Biochemistry, Herlev Hospital (B.G.N.), Herlev, Denmark.

Abstract Cyclosporine may suppress transplant arteriosclerosis; however, it also raises plasma cholesterol, which could promote the disease. Our aim was to test these hypotheses experimentally. In experiment 1 (n=34), cholesterol was clamped at a human level of 5 to 7 mmol/L, and rabbits were given either saline or cyclosporine in a low, medium, or high dose. In experiment 2 (n=15), in which dietary cholesterol was fixed at 0.05 g·kg-1·d-1, and experiment 3 (n=16), in which no dietary cholesterol was added to the chow, rabbits were given either medium-dose cyclosporine, saline, or vehicle. The duration of each experiment was 5 weeks. In experiment 1, cyclosporine attenuated the development of transplant arteriosclerosis dose dependently (trend test: P<.0001). Cyclosporine also suppressed, in a dose-dependent manner, the activation of the immune system (trend test: P<.05) and the presence of T lymphocytes (trend test: P<.0001) and macrophages in the intima (trend test: P<.01). Despite a higher plasma cholesterol level in cyclosporine-treated rabbits compared with saline-treated rabbits in both experiment 2 (4.9 versus 2.9 mmol/L) and experiment 3 (1.6 versus 0.8 mmol/L), transplant arteriosclerosis was significantly reduced by cyclosporine (Mann-Whitney U test: P<.05 and P<.05). These results suggest that cyclosporine suppresses experimental transplant arteriosclerosis dose dependently. Accordingly, in the assessment of the optimal cyclosporine dose to heart-transplanted patients, it should be taken into account that a dose reduction may promote transplant arteriosclerosis.


Key Words: transplantation • arteriosclerosis • rabbits • cyclosporine • cholesterol •




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
V. Fuster, P. R. Moreno, Z. A. Fayad, R. Corti, and J. J. Badimon
Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts
J. Am. Coll. Cardiol., September 20, 2005; 46(6): 937 - 954.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
P. Religa, K. Bojakowski, M. Bojakowska, Z. Gaciong, J. Thyberg, and U. Hedin
Allogenic immune response promotes the accumulation of host-derived smooth muscle cells in transplant arteriosclerosis
Cardiovasc Res, February 1, 2005; 65(2): 535 - 545.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Nilsson, G. K. Hansson, and P. K. Shah
Immunomodulation of Atherosclerosis: Implications for Vaccine Development
Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 18 - 28.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. Murakami, F. Kambe, H. Mitsuyama, K. Okumura, T. Murohara, S. Niwata, R. Yamamoto, and H. Seo
Cyclosporin A Enhances Interleukin-8 Expression by Inducing Activator Protein-1 in Human Aortic Smooth Muscle Cells
Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 2034 - 2040.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
G. J. Schroepfer Jr.
Oxysterols: Modulators of Cholesterol Metabolism and Other Processes
Physiol Rev, January 1, 2000; 80(1): 361 - 554.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. O. Andersen, B. F. Hansen, P. Holm, S. Stender, and B. G. Nordestgaard
Effect of Cyclosporine on Arterial Balloon Injury Lesions in Cholesterol-Clamped Rabbits : T Lymphocyte–Mediated Immune Responses Not Involved in Balloon Injury–Induced Neointimal Proliferation
Arterioscler. Thromb. Vasc. Biol., July 1, 1999; 19(7): 1687 - 1694.
[Abstract] [Full Text] [PDF]